(3-甲苄基)三苯基氯化膦 | 63368-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-甲苄基)三苯基氯化膦
• 中文别名: (3-甲基苄基)三苯基氯化膦；(3-甲基苄基)三苯基氯化磷鎓；3-甲基三苯基氯化磷
• 英文名称: (3-methylbenzyl)triphenylphosphonium chloride
• 英文别名: 3-methylbenzyl triphenylphosphonium chloride；m-methylbenzyltriphenylphosphonium cloride；3-methylbenzyl-triphenylphosphonium chloride；3-Methylbenzyltriphenylphosphoniumchlorid；(3-methylphenyl)methyl-triphenylphosphanium;chloride
• CAS: 63368-37-6
• 化学式: C₂₆H₂₄P*Cl
• 分子量: 402.903
• InChiKey: BNGXYYYYKUGPPF-UHFFFAOYSA-M

物化性质

• 熔点：
  >300℃
• 稳定性/保质期：

  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S37/39
• 储存条件：
  存放在密封容器中，并置于阴凉、干燥处。请确保储存位置远离氧化剂。

SDS

Name:	3-Methylbenzyltriphenylphosphonium chloride 99% Material Safety Data Sheet
Synonym:	[(3-Methylphenyl)methyl]-triphenylphosphonium chloride
CAS:	63368-37-6

Section 1 - Chemical Product MSDS Name:3-Methylbenzyltriphenylphosphonium chloride 99% Material Safety Data Sheet
Synonym:[(3-Methylphenyl)methyl]-triphenylphosphonium chloride

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
63368-37-6	3-Methylbenzyltriphenylphosphonium chl	99	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Use with adequate ventilation. Avoid breathing dust.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 63368-37-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C26H24ClP
Molecular Weight: 402.89

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of phosphorus, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 63368-37-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methylbenzyltriphenylphosphonium chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 63368-37-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 63368-37-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 63368-37-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-甲苄基)三苯基氯化膦 在 18-冠醚-6 、 tin(II) chloride dihdyrate 、 potassium carbonate 、 溶剂黄146 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 13.0h， 生成 (E)-2-(2-(3-methylstyryl)phenyl) isoindoline-1,3-dione
  参考文献：
  名称：

  Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators

  摘要：

  Anti-inflammatory effects of liver X receptor (LXR) ligands are thought to be largely due to LXR-mediated transrepression, whereas side effects are caused by activation of LXR-responsive gene expression (transactivation). Therefore, selective LXR modulators that preferentially exhibit transrepression activity should exhibit anti-inflammatory properties with fewer side effects. Here, we synthesized a series of styrylphenylphthalirnide analogues and evaluated their structure activity relationships focusing on LXRs-transactivating-agonistic/antagonistic activities and transrepressional activity. Among the compounds examined, 171 showed potent LXR-transrepressional activity with high selectivity over transactivating activity and did not show characteristic side effects of LXR-transactivating agonists in cells. This representative compound, 171, was confirmed to have LXR-dependent transrepressional activity and to bind directly to LXR beta. Compound 171 should be useful not only as a chemical tool for studying the biological functions of LXRs transrepression but also as a candidate for a safer agent to treat inflammatory diseases.

  DOI：

  10.1021/acsmedchemlett.5b00170
• 作为产物：
  描述：

  3-甲基苄基氯 、 三苯基膦 以 甲苯 为溶剂， 生成 (3-甲苄基)三苯基氯化膦
  参考文献：
  名称：

  手性亚氨基二磷酸催化高度非对映和对映选择性合成多取代的3,4-二氢-2 H-吡喃：[4 + 2]β，γ-不饱和α-酮酸酯和3-Vilinlindoles的环加成反应

  摘要：

  亚氨基二磷酸被用于催化β，γ-不饱和α-酮酸酯和3-乙烯基吲哚的反电子需杂Diels-Alder反应。合成了具有三个连续立体中心的一系列旋光3,4-二氢-2 H-吡喃衍生物，具有优异的收率（70–99％），非对映选择性（> 20：1）和对映选择性（73–99％）。可以将得到的含有3，4-二氢-2 H-吡喃的吲哚转化为四氢吡喃衍生物，通过简单的氢化还原作用，它可以出现在几种生物活性化合物中。

  DOI：

  10.1021/acs.orglett.9b01675

文献信息

• A Convergent Approach to Cryptophycin 52 Analogues:  Synthesis and Biological Evaluation of a Novel Series of Fragment A Epoxides and Chlorohydrins
  作者：Rima S. Al-awar、James E. Ray、Richard M. Schultz、Sherri L. Andis、Joseph H. Kennedy、Richard E. Moore、Jian Liang、Trimurtulu Golakoti、Gottumukkala V. Subbaraju、Thomas H. Corbett

  DOI：10.1021/jm0203884

  日期：2003.7.1

  intermediate aldehyde prepared from Cryptophycin 53. Substitution on the phenyl ring of fragment A was well tolerated, and several of these analogues were equally or more potent than Cryptophycin 52 when evaluated in vitro in the CCRF-CEM leukemia cell line and in vivo against a murine pancreatic adenocarcinoma.

  隐藻霉素52是隐藻霉素1的合成衍生物，隐藻霉素1是一种从蓝细菌中分离出来的有效的抗微管剂。为了提高分子的效力和水溶性，围绕片段A的苯环展开了结构-活性关系研究（SAR）。使用多种三苯基phosph盐和四氢呋喃盐之间的Wittig烯化反应来获得这些隐藻霉素52类似物。由隐藻霉素53制备的关键中间体醛。在片段A的苯环上的取代具有良好的耐受性，当在CCRF-CEM白血病细胞系中进行体外评估并在体内针对甲氧西林鼠胰腺腺癌。
• [EN] HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE L'ACTIVITÉ MITOCHONDRIALE ET UTILISATIONS ASSOCIÉES
  申请人：UNIV MONTREAL

  公开号：WO2019084662A1

  公开（公告）日：2019-05-09

  Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

  化合物的分子式（I）的杂环化合物及其药用盐已被披露。还披露了这种杂环化合物及其药用盐用于治疗癌症，尤其是对于对线粒体活性抑制和增加活性氧化物（ROS）水平敏感的癌症。这些癌症包括急性髓样白血病（AML），最好是具有某些特征的AML，例如高水平表达一个或多个Homeobox（HOX）网络基因，特定基因的高和/或低表达，存在一个或多个细胞遗传学或分子风险因素，如中等细胞遗传学风险，正常核型（A/K），突变NPM1，突变CEBPA，突变FLT3，突变DNMT3A，突变TET2，突变IDH1，突变IDH2，突变RUNX1，突变WT1，突变SRSF2，具有异常核型的中等细胞遗传学风险（intern(abnK)），三体8（+8）和/或异常染色体（5/7），和/或高白血病干细胞（LSC）频率。
• CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20220089538A1

  公开（公告）日：2022-03-24

  Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R 1 , , R 3 , and L are as defined herein.

  式(I)的化合物及其药用盐、同位素、N-氧化物、溶剂合物和立体异构体，包含它们的药物组合物，制备它们的方法以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，如与疼痛、精神障碍、神经障碍（包括但不限于抑郁症、重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征和躁狂症）、癌症和眼部疾病相关的疾病状态、疾病和症状：其中R1、R3和L如本文所定义。
• [EN] THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE<br/>[FR] CYCLOPENTANES THÉRAPEUTIQUES SUBSTITUÉS POUR RÉDUIRE LA PRESSION INTRAOCULAIRE
  申请人：ALLERGAN INC

  公开号：WO2009006370A1

  公开（公告）日：2009-01-08

  Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2C=C-(CH2)3-, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is -(CH2)m-Ar-(CH2)o- wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 -CH2- may be replaced by S or O, and 1 -CH2-CH2- may be replaced by -CH=CH- or -C≡C-; U1 and U2 are independently selected from -H, =O, -OH, -F, -Cl, and -CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

  本文披露了具有以下化学式（I）的化合物，其中虚线表示键的存在或缺失；Y是有机酸官能团，或其酰胺或酯；或Y是羟甲基或其醚；或Y是四唑基官能团；A是-(CH2)6-，顺式- CH=CH-( )3-，或- C=C-( )3-，其中1或2个碳原子可以被S或O取代；或A是-( )m-Ar-( )o-，其中Ar是间芳基或杂环间芳基，m和o的总和为1、2、3或4，其中1个- -可以被S或O取代，1个- - -可以被-CH=CH-或-C≡C-取代；U1和U2独立选择自-H，=O，-OH，-F，-Cl和-CN；B是芳基或杂芳基，用作眼压降低剂。
• Chemical structure and sweet taste of isocoumarin and related compounds. IX.
  作者：MASATOSHI YAMATO、KOICHI SATO、KUNIKO HASHIGAKI、TAKAJI KOYAMA

  DOI：10.1248/cpb.25.706

  日期：——

  Structural modification of the phenyl moiety (A moiety) of β-(3-hydroxy-4-methoxyphenyl) ethylbenzene (I), which constitute an essential part of phyllodulcin molecules, was attempted to make the relationship between structure and sweet taste clearer. Twenty-four derivatives of A moiety of I were synthesized, the compound (II, IV, V, VI, X, XXII, XXIII, and XXVI) revealed sweet taste and the other compounds were tasteless. On the basis of these data, the taste of these compounds were discussed in connection with the stereochemical hindrance effect of substituents.

  对β-(3-羟基-4-甲氧基苯基)乙基苯（I）的苯基部分（A部分）进行了结构修饰，试图使结构与甜味之间的关系更加明确。合成了I的24种A部分衍生物，其中化合物（II、IV、V、VI、X、XXII、XXIII和XXVI）显示出甜味，而其他化合物则无味。根据这些数据，讨论了这些化合物的味道与取代基的立体化学障碍效应之间的关系。